Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    24615778 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
Conditions: Chronic Lymphocytic Leukemia (CLL);   Lymphoma, Non-Hodgkin (NHL);   Acute Myeloid Leukemia (AML);   Multiple Myeloma (MM)
Intervention: Drug: CAL-101

Study has passed its completion date and status has not been verified in more than two years.